Compare Symbotic Inc (SYM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Symbotic Inc trades at $42.82 (market cap $5.62B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.9× Symbotic Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| SYM | VRTX | |
|---|---|---|
Market Cap | $5.62B | $134.06B |
Sector | Technology | Health |
52-Week High | $87.30 | $557.96 |
52-Week Low | $38.22 | $376.62 |
Enterprise Value | $3.88B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $43.30, up 0.84% today, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $2.25B in 2025 but posted a net loss of $16.94M, though 2026 projections show potential profitability. Analyst consensus is bullish with a $56.50 price target, representing 30% upside potential from current levels. Recent news highlights Symbotic's $22.5B backlog and strategic partnership with Stanford Robotics Center.
SYM presents growth potential with strong revenue projections and massive backlog, but faces risks from customer concentration (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1,082.5, though negative EBITDA and thin margins warrant caution. Institutional interest remains positive with new investments, but insider selling and legal investigations create near-term headwinds.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
